MC

465.5

-1.41%↓

SANES

9.62

+0.34%↑

SAF

305.9

-0.29%↓

BBVA

18.215

+0.28%↑

BNP

87.16

+1.36%↑

MC

465.5

-1.41%↓

SANES

9.62

+0.34%↑

SAF

305.9

-0.29%↓

BBVA

18.215

+0.28%↑

BNP

87.16

+1.36%↑

MC

465.5

-1.41%↓

SANES

9.62

+0.34%↑

SAF

305.9

-0.29%↓

BBVA

18.215

+0.28%↑

BNP

87.16

+1.36%↑

MC

465.5

-1.41%↓

SANES

9.62

+0.34%↑

SAF

305.9

-0.29%↓

BBVA

18.215

+0.28%↑

BNP

87.16

+1.36%↑

MC

465.5

-1.41%↓

SANES

9.62

+0.34%↑

SAF

305.9

-0.29%↓

BBVA

18.215

+0.28%↑

BNP

87.16

+1.36%↑

Search

Sartorius Stedim Biotech.

Abierto

SectorFinanzas

173.3 1.32

Resumen

Variación precio

24h

Actual

Mínimo

170.35

Máximo

177.75

Métricas clave

By Trading Economics

Ingresos

-17M

47M

Ventas

67M

772M

P/B

Media del Sector

59.506

31.512

BPA

0.94

Rentabilidad por dividendo

0.42

Margen de beneficios

6.125

Empleados

9,753

EBITDA

-19M

199M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+36.14% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.42%

4.62%

Próximas Ganancias

23 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-2.4B

16B

Apertura anterior

171.98

Cierre anterior

173.3

Noticias sobre sentimiento de mercado

By Acuity

14%

86%

16 / 441 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Sartorius Stedim Biotech. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 mar 2026, 22:42 UTC

Ganancias

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mar 2026, 21:40 UTC

Ganancias

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mar 2026, 23:56 UTC

Charlas de Mercado

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mar 2026, 23:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 mar 2026, 23:42 UTC

Charlas de Mercado

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mar 2026, 23:38 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mar 2026, 23:24 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

17 mar 2026, 23:24 UTC

Charlas de Mercado

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mar 2026, 22:22 UTC

Charlas de Mercado

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mar 2026, 22:20 UTC

Ganancias

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mar 2026, 22:20 UTC

Ganancias

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mar 2026, 22:07 UTC

Ganancias

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mar 2026, 22:05 UTC

Ganancias

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mar 2026, 22:04 UTC

Ganancias

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mar 2026, 22:03 UTC

Ganancias

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mar 2026, 21:26 UTC

Ganancias

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mar 2026, 21:09 UTC

Ganancias

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mar 2026, 21:08 UTC

Ganancias

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mar 2026, 21:08 UTC

Ganancias

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:07 UTC

Ganancias

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:06 UTC

Ganancias

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Net $757.2M >ATD.T

17 mar 2026, 20:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Sartorius Stedim Biotech. previsión

Precio Objetivo

By TipRanks

36.14% repunte

Estimación a 12 Meses

Media 237.43 EUR  36.14%

Máximo 262 EUR

Mínimo 210 EUR

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sartorius Stedim Biotech. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

6

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

202.7 / 211.7Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

16 / 441 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat